International Journal of Cardiology 232 (2017) 348

Contents lists available at ScienceDirect

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard

Corrigendum

Corrigendum to 'Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology' [Int. J. Cardiol. 220 (2016) 131–136]

Ebru Ertekin [a,1], Iris M. van Hagen [a,1], Amar M. Salam [b,1], Titia P.E. Ruys [a,1], Mark R. Johnson [c,1], Jana Popelova [d,1], William A. Parsonage [e,1], Zeinab Ashour [f,1], Avraham Shotan [g,1], José M. Oliver [h,1], Gruschen R. Veldtman [i,1], Roger Hall [j,1], Jolien W. Roos-Hesselink [a,k,*,1]

[a] Erasmus University Medical Center, Rotterdam, The Netherlands
[b] Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
[c] Imperial College School of Medicine, Chelsea and Westminster Hospital, London, United Kingdom
[d] Hospital Na Homolce & Pediatric Heart Center University Hospital Motol, Prague, Czech Republic
[e] Royal Brisbane & Women's Hospital, Herston, Australia
[f] Cairo University, Cairo, Egypt
[g] Hillel Yaffe Medical Center, Hadera, Israel
[h] Adult Congenital Heart Disease Unit, La Paz University Hospital, Madrid, Spain
[i] Adolescent and Adult Congenital Heart Program, Cincinnati Children's Hospital, Cincinnati,United States
[j] Norwich Medical School, University of East Anglia, Norwich, United Kingdom
[k] Fellow of the European Society of Cardiology, Sophia Antipolis, Cedex, France

The authors regret that some dates of sponsor's involvement in the program were incorrectly reported in the initial published paper, therefore please consider the below corrected information:

Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer (2009–2018), Boehringer Ingelheim (2009–2016), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2017), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2009–2018).

The authors would like to apologise for any inconvenience caused.

DOI of original article: http://dx.doi.org/10.1016/j.ijcard.2016.06.061.
* Corresponding author at: Department of Cardiology, Office Ba 308, Erasmus University Medical Center, PO Box 2040, 3000, CA, Rotterdam, The Netherlands.
E-mail address: j.roos@erasmusmc.nl (J.W. Roos-Hesselink).
[1] This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

http://dx.doi.org/10.1016/j.ijcard.2017.01.077
0167-5273/© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).